JMP Securities Reiterates Market Outperform on Summit Therapeutics, Maintains $40 Price Target

Benzinga · 09/03/2025 13:34
JMP Securities analyst Reni J. Benjamin reiterates Summit Therapeutics (NASDAQ:SMMT) with a Market Outperform and maintains $40 price target.